Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Paying $1.1bn for Heartware five years ago was not the company’s smartest move.
The world’s biggest medtech expects great things from its new surgical robot, but its best shot at leading a market with a new product remains renal denervation.
The pivotal trial of Medtronic’s hypertension device came out more than a year ago, yet the company has still not sought approval.
Acumen is the latest player to take aim at amyloid, but competition is fierce.
Biogen needs blood tests for amyloid beta to progress quickly – and several are in the pipeline.
The pricing of Aduhelm has been compared to that of Sovaldi, but this ignores the fact that Sovaldi actually worked.
Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.
Huge hopes for diabetes and Alzheimer’s projects swell Lilly’s pipeline valuation, with Glaxosmithkline and Abbvie looking bare in comparison.
But this week two transactions did squeak through.
But with Derm Assist available free, how will the company make money?
Protagonist and Autolus rose on Friday, but there were losses for Curis, Aptose, Forma and Equillium, among others.
The anti-Tigit MAb domvanalimab will generate key clinical results any day; will they be good enough for Gilead to opt in?
A small molecule for alpha-1 antitrypsin deficiency faces a key clinical test, and its chances of success aren’t good.
Key catalysts approach for Orphazyme, Gemini and Immutep.